ORBIMED ADVISORS LLC 组合持仓
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001055951
什么是 13F 持仓报告?谁需要申报、何时申报 · 13F 持仓报告看不到什么
Q1 2024 · 112 持仓数 · 申报总市值 $5.33B · 前十大集中度 39.9% · 更新于 2026-10-18
最后更新: 2026-10-18 · 来源: SEC EDGAR Form 13F-HR
换手率: 62.8% · 26 新建 · 32 减仓 · 33 清仓
主动份额(对标 S&P 500): 95.4% · 对比 QQQ: 99.0% — 组合中区别于指数权重的部分(越高越主动) · 排名
估算季度收益 (Q2 2026 → Q3 2026): -11.1% · 对比 SPY -13.2% · 上季市值 $4.97B — 按上季持仓市值以本季涨跌加权估算 · 排名
估算季内收益 (Q3 2026 → 最新收盘): -4.2% · 对比 SPY -6.3% · 最新申报市值 $4.91B — 最新申报持仓按季内至今涨跌加权(仍在变动) · 排名
在 Q1 2024 的 13F 申报中,ORBIMED ADVISORS LLC 披露了 112 个股票持仓,合计申报市值 $5.33B。前十大持仓占申报市值的 39.9%,组合属于中度集中型。HoldingsHub 将其风格标签归纳为 Mid / Health Tilt / High Turnover。
截至 Q1 2024,最大的披露持仓包括 SVA($340.00M)、LLY($280.69M)、EWTX($274.00M)。行业分布上,占比最高的板块为 医疗保健 77.0%, 可选消费 1.6%。较上一季度,板块上主要增配 Health Care(+8.7 个百分点),同时减配 Other(-8.5 个百分点)。
与上一季度相比,ORBIMED ADVISORS LLC 新建 26 个仓位、减持 32 个、清仓 33 个,换手率约 62.8%。持仓组合与上季度的重合率约为 71%。
Q1 2024 最大新建仓位为 AVBP($54.07M)、CYTK($47.86M)、QTTB($38.39M)。
较上季度清仓的 33 个仓位中,金额最大的是 RYZB($147.05M)、GRCL($93.46M)、UTHR($84.90M)。
以上数据来自该基金的 SEC 13F 申报。13F 需在季度结束后 45 天内提交,仅涵盖 10 万美元以上的多头持仓,不含空头与非 13F 资产类别,因此本页反映的是季末快照,并非基金的实时持仓。
新建仓(Q1 2024)
- AVBP ARRIVENT BIOPHARMA INC · $54.07M
- CYTK CYTOKINETICS INC · $47.86M
- QTTB Q32 BIO INC · $38.39M
- ESPR ESPERION THERAPEUTICS INC NE · $36.74M
- PRAX PRAXIS PRECISION MEDICINES I · $28.10M
- MLYS MINERALYS THERAPEUTICS INC · $26.10M
- RNAM AVIDITY BIOSCIENCES INC · $25.37M
- DYN DYNE THERAPEUTICS INC · $20.11M
完全清仓(较上季)
- RYZB RAYZEBIO INC · 上季市值: $147.05M
- GRCL GRACELL BIOTECHNOLOGIES INC · 上季市值: $93.46M
- UTHR UNITED THERAPEUTICS CORP DEL · 上季市值: $84.90M
- THRX THESEUS PHARMACEUTICALS INC · 上季市值: $71.74M
- RCM R1 RCM INC · 上季市值: $50.77M
- HUM HUMANA INC · 上季市值: $50.31M · 历史持仓
- IOVA IOVANCE BIOTHERAPEUTICS INC · 上季市值: $38.27M
- FUSN FUSION PHARMACEUTICALS INC · 上季市值: $30.01M
内部人交易(Form 4)
ORBIMED ADVISORS LLC 最新申报的 SEC Form 4 买卖——当该基金对某只股票的持股超过 10% 后,交易须在两个交易日内申报。
| 交易日期 | 交易方向 | 证券 | 股数 | 价格 | 申报 |
|---|---|---|---|---|---|
| 2026-11-10 | 买入 | Electra Therapeutics, Inc. | 2,000 | $8.45 | SEC 原文 |
| 2026-11-10 | 买入 | Electra Therapeutics, Inc. | 20,700 | $8.45 | SEC 原文 |
| 2026-11-09 | 买入 | Electra Therapeutics, Inc. | 16,000 | $8.24 | SEC 原文 |
| 2026-11-09 | 买入 | Electra Therapeutics, Inc. | 4,000 | $8.24 | SEC 原文 |
| 2026-11-06 | 买入 | Electra Therapeutics, Inc. | 39,600 | $7.85 | SEC 原文 |
| 2026-11-06 | 买入 | Electra Therapeutics, Inc. | 9,816 | $7.85 | SEC 原文 |
| 2026-11-05 | 买入 | Electra Therapeutics, Inc. | 125,200 | $7.31 | SEC 原文 |
| 2026-11-05 | 买入 | Electra Therapeutics, Inc. | 30,891 | $7.31 | SEC 原文 |
基金介绍
ORBIMED ADVISORS LLC是一家总部位于纽约的投资公司,由Samuel Isen等人创立,专注于医疗保健和生命科学领域的投资。
投资方法
ORBIMED采用长期投资策略,专注于医疗保健和生命科学领域。公司拥有超过30年的行业经验,在全球范围内寻找投资机会。
资产类别
ORBIMED投资于多种资产类别,包括公开市场股票(通过SEC 13F文件可见)、私募股权、债务工具、风险投资以及特殊情况/困境债务。
关键人物
Samuel Isen - 联合创始人和管理合伙人
Steven Bloom - 联合创始人和管理合伙人
公司还有多位其他管理合伙人和投资专业人士
notable facts
ORBIMED是美国最大的医疗保健投资公司之一,在全球多个城市设有办公室,包括纽约、波士顿、旧金山、伦敦和香港。
本信息基于公开披露,投资决策应参考官方文件。
| # | 公司 | 股数 | 金额 | 权重 | Allocation | 变化 |
|---|---|---|---|---|---|---|
| 1 |
|
2.72M | $340.00M | 6.38% | 持有 | |
| 2 |
|
360.80K | $280.69M | 5.26% | 减持 | |
| 3 |
|
15.02M | $274.00M | 5.14% | 增持 | |
| 4 |
|
3.27M | $224.17M | 4.20% | 减持 | |
| 5 |
|
493.10K | $196.79M | 3.69% | 减持 | |
| 6 |
|
900.90K | $194.26M | 3.64% | 增持 | |
| 7 |
|
1.32M | $173.65M | 3.26% | 增持 | |
| 8 |
|
4.28M | $160.97M | 3.02% | 增持 | |
| 9 |
|
9.00M | $158.28M | 2.97% | 持有 | |
| 10 |
|
1.17M | $123.33M | 2.31% | 减持 | |
| 11 |
|
1.28M | $111.66M | 2.09% | 减持 | |
| 12 |
|
2.68M | $106.25M | 1.99% | 增持 | |
| 13 |
|
1.70M | $105.98M | 1.99% | 持有 | |
| 14 |
|
269.00K | $96.27M | 1.81% | 持有 | |
| 15 |
|
9.24M | $94.44M | 1.77% | 持有 | |
| 16 |
|
697.50K | $90.30M | 1.69% | 持有 | |
| 17 |
|
2.01M | $87.26M | 1.64% | 减持 | |
| 18 |
|
168.10K | $87.17M | 1.64% | 增持 | |
| 19 |
|
73.11M | $85.54M | 1.60% | 持有 | |
| 20 |
|
2.61M | $85.44M | 1.60% | 减持 | |
| 21 |
|
1.71M | $84.03M | 1.58% | 减持 | |
| 22 |
|
1.27M | $83.99M | 1.57% | 持有 | |
| 23 |
|
899.43K | $82.26M | 1.54% | 减持 | |
| 24 |
|
132.00K | $76.72M | 1.44% | 减持 | |
| 25 |
|
1.07M | $72.83M | 1.37% | 减持 | |
| 26 |
|
1.39M | $64.83M | 1.22% | 减持 | |
| 27 |
|
3.57M | $63.49M | 1.19% | 减持 | |
| 28 |
|
151.60K | $59.69M | 1.12% | 增持 | |
| 29 |
|
174.10K | $58.49M | 1.10% | 增持 | |
| 30 |
|
423.10K | $58.35M | 1.09% | 减持 | |
| 31 |
|
3.40M | $54.67M | 1.02% | 减持 | |
| 32 |
|
5.78M | $54.55M | 1.02% | 持有 | |
| 33 |
|
3.03M | $54.07M | 1.01% | 新进 | |
| 34 |
|
4.00M | $52.85M | 0.99% | 持有 | |
| 35 |
|
10.91M | $51.71M | 0.97% | 持有 | |
| 36 |
|
122.70K | $51.29M | 0.96% | 减持 | |
| 37 |
|
7.62M | $49.98M | 0.94% | 持有 | |
| 38 |
|
682.70K | $47.86M | 0.90% | 新进 | |
| 39 |
|
718.90K | $47.77M | 0.90% | 减持 | |
| 40 |
|
22.36M | $44.28M | 0.83% | 持有 | |
| 41 |
|
12.89M | $42.55M | 0.80% | 增持 | |
| 42 |
|
1.75M | $41.63M | 0.78% | 持有 | |
| 43 |
|
2.25M | $38.39M | 0.72% | 新进 | |
| 44 |
|
13.71M | $36.74M | 0.69% | 新进 | |
| 45 |
|
12.05M | $35.97M | 0.68% | 持有 | |
| 46 |
|
70.00K | $34.63M | 0.65% | 持有 | |
| 47 |
|
704.84K | $30.54M | 0.57% | 增持 | |
| 48 |
|
2.72M | $30.31M | 0.57% | 减持 | |
| 49 |
|
675.87K | $29.14M | 0.55% | 减持 | |
| 50 |
|
460.51K | $28.10M | 0.53% | 新进 | |
常见问题
What did ORBIMED ADVISORS LLC buy in 2024-Q1?
In its 2024-Q1 13F filing, ORBIMED ADVISORS LLC reported 112 equity positions worth $5.33B in aggregate; its largest disclosed positions were SVA ($340.00M), LLY ($280.69M), EWTX ($274.00M).
How large is ORBIMED ADVISORS LLC's portfolio?
ORBIMED ADVISORS LLC reported $5.33B of long equity holdings across 112 positions as of 2024-Q1. Top-10 holdings account for 39.9% of reported value.
What is ORBIMED ADVISORS LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.